CDK4 and neoplasm: To identify potential tumour prognostic and predictive factors influencing the efficacy of CDK4/6i, we performed a transcriptomic analysis using the NanoString Breast Cancer 360TM (BC360TM) panel in patients with matched tumour tissue and clinical data (Figure 1A and Table S1).